"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New Jersey drugmaker is confident that a broad label will land its product an ...

“FDA’s approval of IMAAVYTM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and ...

Notably, the FDA granted approval for IMAAVY, a new monoclonal antibody treatment for generalized myasthenia gravis, potentially strengthening J&J's portfolio in autoimmune conditions ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Imaavy plus standard of care led to improvements at ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle ...

The FDA has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for the treatment of treatment of generalized myasthenia gravis (gMG). Following FDA Priority Review designation, this approval ...

On April 30, 2025, the FDA approved nipocalimab-aahu (Imaavy; Johnson & Johnson), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG) in adult and ...

The drug, which J&J will sell as Imaavy, was cleared by the FDA to treat adults and children 12 years of age or older who have an autoimmune condition known as generalized myasthenia gravis. The ...

Then, sometime in 2016, she experienced a condition called ptosis or drooping of both her upper eyelids. Alina was referred to a neurologist at Hospital Serdang in Selangor. After undergoing several ...